Life Sciences

  • May 14, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Members of Congress approved language in a funding bill that would block the rescheduling of marijuana, Colorado lawmakers gave final approval to a bill to fund research into the psychedelic ibogaine and authorize the establishment of licensed treatment centers, and Rhode Island lawmakers introduced legislation to eliminate geographic criteria from the state's cannabis social equity program.

  • May 14, 2026

    NC Republicans Want Fetal Personhood Question On '26 Ballot

    Two Republicans in the North Carolina House who have a history of advancing so-called fetal personhood bills have made another attempt to put a constitutional amendment to voters in November to decide if life begins at fertilization.

  • May 14, 2026

    Takeda To Pay $13.6M Over Antidepressant Drug Kickbacks

    Takeda Pharmaceuticals will pay $13.6 million to end allegations that it caused false Medicaid claims by providing kickbacks to healthcare providers to push prescriptions of its antidepressant drug Trintellix, the U.S. Department of Justice announced Thursday.

  • May 14, 2026

    Human Reproduction Proves Talc Can Reach Ovaries, Jury Told

    A medical oncologist on Thursday told a Los Angeles bellwether jury considering claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer that the female reproductive system is an "open" system where talc can migrate to the ovaries, and that "we wouldn't exist" if that was not the case.

  • May 14, 2026

    Squires Walks Back 5 More IPR Grants Over Inconsistent Args

    U.S. Patent and Trademark Office Director John Squires has reversed earlier decisions granting five petitions for patent review, citing what he called the challengers' inconsistent positions in parallel proceedings and explaining that four petitions he denied in previous bulk orders were also rejected for the same reasons. 

  • May 14, 2026

    House Passes Bill To Narrow Biofuel Blending Exemption

    The U.S. House of Representatives has passed a bill that would lift summertime restrictions on the sale of higher-ethanol fuel and tighten requirements for a biofuel blending exemption for small refineries.

  • May 14, 2026

    Med Device Co.'s CEO Touted Growth, Netted $39M, Suit Says

    Medical device maker Integer Holdings Corp.'s former CEO overstated growth prospects of a manufacturing program for the company's electrophysiology business, inflating the firm's stock price and allowing him to reap a nearly $39 million "windfall net profit," according to an investor's derivative lawsuit in Texas federal court.

  • May 14, 2026

    Albertsons Not Covered In Opioid Litigation, Del. Judge Says

    Albertsons isn't entitled to defense or indemnity for more than 100 suits accusing the pharmacy and grocery chain of fueling the opioid epidemic, a Delaware state court ruled, tracking the state high court's rulings in nearly identical disputes involving Rite Aid and CVS.

  • May 14, 2026

    Insider Trading Case Shows BigLaw Associate Vetting Gaps

    A BigLaw attorney who was able to move through three major firms while allegedly orchestrating a massive insider trading scheme may have been aided by relatively loose hiring practices for associates that firms may consider strengthening moving forward, recruiting experts told Law360.

  • May 14, 2026

    Fortive, Subsidiary Seek Early Win In Wrongful Firing Suit

    Technology company Fortive and a medical equipment subsidiary asked a Colorado federal judge for an early win in a former regional sales director's lawsuit alleging she was fired for raising concerns about compliance with anti-kickback rules, contending the subsidiary terminated her due to a restructuring and that Fortive wasn't her employer.

  • May 14, 2026

    High Court Maintains Abortion Pill Access Amid Circuit Appeal

    The U.S. Supreme Court on Thursday extended a stay preserving telehealth access to the abortion medication mifepristone while the Fifth Circuit weighs a challenge to the mail-order distribution of the pill.

  • May 14, 2026

    Takeda Cashed In From Delay Of Generic IBS Drug, Jury Told

    Drug buyers urged a Massachusetts federal jury on Thursday to find that Takeda Pharmaceuticals conspired with another drugmaker to keep a generic version of anticonstipation drug Amitiza off the market in order to boost its own profits. 

  • May 14, 2026

    BeiGene Must Face AbbVie's Chemical Trade Secret Claims

    An Illinois federal judge has denied oncological research company BeiGene's request to escape claims from AbbVie Inc. that it poached a retired scientist to obtain trade secrets related to a certain chemical compound, saying BeiGene failed to back up its arguments.

  • May 14, 2026

    Ex-Investor Seeks Records On $8.9B Thermo Fisher Payout

    A former equity holder of Clario Holdings Inc., a clinical-trial technology company, has sued in the Delaware Chancery Court, seeking records she says she needs to understand how her payout was calculated after Thermo Fisher Scientific Inc.'s $8.875 billion cash acquisition of Clario.

  • May 14, 2026

    Ga. Panel Quiet On Fate Of $20M Bard Cancer Verdict

    A Georgia appellate panel gave few indications Thursday of whether it would order a new trial in a former C.R. Bard worker's lawsuit alleging that exposure to ethylene oxide caused his cancer, weighing whether a mistrial on punitive damages necessitates scrapping a $20 million compensatory damages verdict.

  • May 14, 2026

    Time For Trial, Judge Says, Nixing DQ Appeal In Generics MDL

    A Pennsylvania federal judge has refused to let generic-drug makers seek Third Circuit intervention in their bid to disqualify the lead counsel for insurers Humana and Molina, concluding the fight would only further delay the long-running case ahead of its first trial in the price-fixing multidistrict litigation.

  • May 13, 2026

    Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug

    The Federal Circuit on Wednesday upheld a lower court's rejection of Actelion Pharmaceuticals' patent case against Viatris Inc. over its planned generic version of Actelion's hypertension drug, finding no issues with the court's approach to pH measurement in the patent.

  • May 13, 2026

    'Powerful' Risk For Women Using Talc, UC Prof Tells Jury

    An epidemiology professor at the University of California, San Francisco testified Wednesday in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused deadly ovarian cancer in three women, saying there are multiple studies concluding the product increases the risk of the disease, including one finding a "very powerful" risk.

  • May 13, 2026

    3 NJ Employers Accused Of Pregnancy Discrimination

    A New Jersey hospital system, a laboratory company and a cleaning business must answer to allegations that they engaged in pregnancy discrimination in the workplace, state enforcers said this week.

  • May 13, 2026

    Walgreens Investors' Opioid Suit Is Time-Barred, Judge Says

    Pharmacy giant Walgreens no longer faces a proposed class action alleging it hurt investors when it disclosed opioid-related litigation losses after a Chicago federal judge found the claims were time-barred.

  • May 13, 2026

    Pa. Jury Finds Dispensary Subjected Fired Manager To Bias

    A Pennsylvania federal jury has awarded $203,500 to a dispensary employee who claimed Restore Integrative Wellness Center discriminated against him by terminating his employment after he went on leave to recover from injuries sustained in a car accident.

  • May 13, 2026

    Bayer, Buyers Get Final OK Of $4.85M Benzene Settlement

    A New Jersey federal judge on Wednesday gave final approval to a $4.85 million settlement to end claims against Bayer Healthcare LLC and others alleging that antifungal products were contaminated with benzene.

  • May 13, 2026

    Becton Hernia Mesh Antitrust Case Survives Dismissal

    A Pennsylvania federal court has refused to toss an antitrust case from Tela Bio Inc. accusing Becton Dickinson & Co. of abusing its dominant position in the hernia mesh market to block competing products.

  • May 13, 2026

    Conn. Doctor Asked To Pay $880K In IVF Fraud Dispute

    Two people who accused a reproductive endocrinologist of using his own sperm to impregnate their mothers have proposed that the doctor settle their suit against him for a total of $880,000, according to separate offers filed in Connecticut state court.

  • May 13, 2026

    Crowell & Moring Opens Minneapolis Office With 8 Lawyers

    Crowell & Moring LLP announced Wednesday that it is deepening its commitment to Minnesota by opening a new office in Minneapolis with a team of eight attorneys and said it's expecting more growth in the near future.

Expert Analysis

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

  • 2 Strands Of Patent Law In High Court's 'Skinny Label' Case

    Author Photo

    Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.

  • Why MDLs Slow Down — And How To Speed Them Up

    Author Photo

    Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.